Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management (Current Clinical Oncology)

In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.

Summarizes current research on the biology and practical management of myeloproliferative disorders, low-grade lymphomas, and chronic leukemias, distinguishing these disorders from large-cell lymphoma and Hodgkin's disease. Special attention is given to the mechanisms of disease progression, with information on new antineoplastic pharmacology. The volume's 12 contributions, written by specialists in the field, include such topics as the biology, diagnosis, and treatment of hairy cell leukemia; myeloproliferative syndromes; and Hodgkin's Disease. Suitable for practitioners in hematologic oncology, oncology nurses, and pharmaceutical researchers working to develop targeted therapies. Annotation c. Book News, Inc., Portland, OR

Doody Review Services

Reviewer:ronald gartenhaus, MD(Northwestern University Feinberg School of Medicine)
Description:The book provides a concise and up-to-date review of the most relevant topics in malignant hematology, excluding acute leukemias and high grade lymphomas. It is an excellent general overview, but perhaps does not give enough detail in the treatment section for practicing oncologists.
Purpose:The purpose is to provide novel insights into molecular biology of chronic hematologic neoplasms and discuss potential novel targets for treatment in this new period of antineoplastic pharmacology. These objectives are well met, and the book is an excellent addition in this rapidly changing field.
Audience:The book is intended for all those with an interest in cancer biology and management including practicing hematologists/oncologists, fellows, researchers, and residents. The authors are highly credible authorities in their fields.
Features:The book summarizes well the most recent insights into molecular pathogenesis of chronic hematologic diseases including chronic leukemias, myelo- and lymphoproliferative diseases, lymphomas and multiple myeloma, and their relevance for assessment of prognosis and management decisions. The results of trials evaluating novel targeted therapies are presented, succinctly providing reader with the most current information.
Assessment:This is a very useful book since it covers the most recent achievements and "hot" topics in chronic hematologic diseases in a concise format. The up-to-date information that it provides might not be available in larger textbooks, and thus it is highly recommended for practitioners and researchers.

In the last decade advances in basic and clinical research on chronic leukemias and lymphomas -- slowly progressive diseases of the blood and bone marrow -- have produced a host of remarkable therapies, including the use of unique small molecules targeted at specific genetic lesions: pro-apoptotic drugs, monoclonal antibodies, and adoptive immunotherapy. In Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of chronic myeloproliferative and lymphoproliferative disorders, the authors place special emphasis on such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Among the disease models considered for chronic lymphocytic leukemia, low-grade lymphoma, and chronic myelogenous leukemia are impairments of the apoptotic mechanisms, as well as specific molecular events that initiate proliferation. Both models of oncogenesis may lead to novel therapeutic targets, such as purine nucleoside analogs for chronic lymphocytic leukemias, monoclonal antibodies for follicular lymphomas, and STI-571 (Gleevec) for chronic myelogenous leukemia. Comprehensive and up-to-date, Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management is a unique book devoted to summarizing both the basic biology and the practical management of myeloproliferative disorders, low grade lymphomas, and chronic leukemias, distinguishing these disorders from large-cell lymphoma and Hodgkin's disease. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology